Sanofi Takes a $120M Hit as Potential Dengue Vaccine Blockbuster Dealt Safety Blow Post author:Sam Post published:November 29, 2017 Post category:BioPharma Sanofi’s setback could open the door for rival drugmaker Takeda. Source: BioSpace You Might Also Like 3 Biotechs Facing Stiff Headwinds in 2018 February 13, 2018 SoCal's Regulus Sinks After AstraZeneca PLC Bails on Lead NASH Drug June 11, 2017 Incyte Discloses Promising New Data in Combo Drug Trial With Merck & Co.'s Keytruda August 30, 2017
